Cantor Fitzgerald Reaffirms Overweight Rating for COMPASS Pathways (NASDAQ:CMPS)

Cantor Fitzgerald reiterated their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS - Free Report) in a research report sent to investors on Friday morning,Benzinga reports.

A number of other analysts also recently weighed in on the company. Canaccord Genuity Group decreased their price objective on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $45.00 target price on shares of COMPASS Pathways in a report on Tuesday, March 4th. Royal Bank of Canada restated an "outperform" rating and set a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th. Finally, Stifel Nicolaus started coverage on shares of COMPASS Pathways in a research report on Thursday, February 27th. They set a "buy" rating and a $11.00 price objective for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $21.83.

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS traded down $0.10 during mid-day trading on Friday, hitting $2.77. 386,639 shares of the stock traded hands, compared to its average volume of 750,083. COMPASS Pathways has a twelve month low of $2.72 and a twelve month high of $10.31. The firm has a 50 day simple moving average of $3.85 and a two-hundred day simple moving average of $4.68. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The company has a market cap of $256.24 million, a PE ratio of -1.26 and a beta of 2.29.

Remove Ads

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). As a group, equities research analysts forecast that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Hedge Funds Weigh In On COMPASS Pathways

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of COMPASS Pathways in the fourth quarter worth approximately $41,000. Flagship Harbor Advisors LLC bought a new stake in shares of COMPASS Pathways in the fourth quarter worth about $43,000. Wealthfront Advisers LLC bought a new position in shares of COMPASS Pathways during the fourth quarter valued at approximately $43,000. Conservest Capital Advisors Inc. raised its holdings in COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Simplify Asset Management Inc. purchased a new stake in COMPASS Pathways in the fourth quarter worth about $54,000. 46.19% of the stock is owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.